Apnimed at a glance
As of- [1] Market cap: stockanalysis.com, September 4, 2026
- [2] Founded: Wikidata (retrieved September 16, 2026)
- [3] Headquarters: Apnimed (retrieved September 5, 2026)
What Apnimed does
Apnimed is a late-stage pharmaceutical company developing oral drugs for obstructive sleep apnea and related breathing disorders.[1] It was founded in 2017.[2] The company is based in Cambridge, Massachusetts.[1] Its lead candidate, AD109, is an experimental once-daily pill for the condition.[2] AD109 has completed two Phase 3 trials covering mild, moderate and severe obstructive sleep apnea.[1] The FDA accepted its New Drug Application and set a PDUFA target action date of February 28, 2027.[3] The company estimates 80 million people in the U.S. live with obstructive sleep apnea, many of them untreated.[3] Apnimed arranged a senior secured credit facility of up to $150 million with funds managed by HealthCare Royalty Partners.[3] It also sold its interest in Shionogi-Apnimed Sleep Science for $100 million upfront, with possible milestones and royalties.[3] Apnimed began trading on the Nasdaq Global Select Market under the ticker APMD on July 31, 2026.[1] The financing is meant to prepare for a possible U.S. launch of Oxnimbi if the FDA approves it.[3]
Leadership
- Kevin Lind is chief executive.[3]
Is this your company? Get featured or correct your listing →
Company Snapshot
Apnimed is a biotech company, based in Cambridge, Massachusetts, USA, founded 2017.
Recent changes
- Sep 4, 2026Sep 4, 2026First reported market cap: $1.52B stockanalysis.com
- Jul 31, 2026Jul 31, 2026Apnimed Soars 37% in Nasdaq Debut for Sleep Apnea Pill Pulse story
- Jul 31, 2026Jul 31, 2026Apnimed Prices Upsized IPO at $16, Raises $192M Pulse story
- Jul 27, 2026Jul 27, 2026Apnimed Launches $150M IPO for Sleep Apnea Pill Pulse story
- Jul 27, 2026Jul 27, 2026Apnimed Launches $150M IPO For First Sleep Apnea Pill Pulse story
Earlier changes (1)
- Jul 10, 2026Jul 10, 2026Apnimed Files for Nasdaq IPO on First Oral Sleep Apnea Pill Pulse story
Investors
Latest Pulse
- Aug 5, 2026Attovia Prices $289M Nasdaq IPO at $17 a ShareAttovia Therapeutics priced 17 million shares at $17 to raise $289M on Nasdaq under the ticker ATTO, the largest operating-company listing of the first week of August.→
- Aug 3, 2026Consumer IPOs Are Getting Crushed While Biotech PopsJersey Mike's opened 9% below its IPO price the same day Reformation traded flat, while Apnimed popped 37.5% days later -- public investors are rewarding unmet-need biotech and discounting mature consumer brands.→
- Aug 1, 2026Why Robotics Is Quietly Becoming the SPAC Market's Favorite ExitBetween Agility Robotics' $2.5B SPAC merger and Michael Klein's newest blank-check vehicle, 2026's SPAC revival is being built on capital-intensive robotics and infrastructure, not the last cycle's meme stocks.→
- Jul 31, 2026The IPO Window Is Splitting Into Two Very Different TiersThis week's debuts split the 2026 IPO market sharply: differentiated biotech stories got double-digit pops, while mature, sponsor-backed consumer brands opened flat or down regardless of profitability.→
- Jul 31, 2026Apnimed Soars 37% in Nasdaq Debut for Sleep Apnea PillApnimed shares jumped as much as 37.5% in their Nasdaq debut after the Phase 3 biotech priced its upsized IPO at $16 a share, raising $192 million to fund what could become the first FDA-approved pill for obstructive sleep apnea.→
- Jul 31, 2026Apnimed Prices Upsized IPO at $16, Raises $192MApnimed priced an upsized IPO at $16 per share, raising $192 million ahead of its Nasdaq debut under ticker APMD, betting on the first potential FDA-approved pill for obstructive sleep apnea.→
- Jul 30, 2026Reformation Debuts on NYSE, Raises $210.9MSustainable womenswear brand Reformation priced its IPO at $15 a share, raising $210.9 million and debuting on the NYSE at a roughly $886 million market value backed by private equity firm Permira.→
- Jul 29, 2026Goldman-Backed Attovia Sets Terms for $200M Nasdaq IPOAttovia Therapeutics set terms for a Nasdaq IPO, offering 12.5 million shares at $15-17 to raise up to $212.5 million, advancing its Phase 1 itch and eczema drug candidates toward a public listing under ticker ATTO.→
- Jul 27, 2026Apnimed Launches $150M IPO for Sleep Apnea PillApnimed launched a $150-160 million IPO for a pill that could become the first FDA-approved treatment for obstructive sleep apnea.→
- Jul 27, 2026Apnimed Launches $150M IPO For First Sleep Apnea PillShionogi-backed Apnimed launched a $150 million IPO for its once-daily obstructive sleep apnea pill AD109, targeting a Thursday pricing ahead of a Friday NASDAQ debut.→
Coverage Timeline
newest first- Aug 3, 2026IPOConsumer IPOs Are Getting Crushed While Biotech Pops→
- Jul 31, 2026IPOApnimed Soars 37% in Nasdaq Debut for Sleep Apnea Pill$192M IPO→
- Jul 31, 2026IPOApnimed Prices Upsized IPO at $16, Raises $192M$192M IPO→
- Jul 27, 2026IPOApnimed Launches $150M IPO for Sleep Apnea Pill$150M-$160M IPO→
- Jul 27, 2026IPOApnimed Launches $150M IPO For First Sleep Apnea Pillup to $150M IPO→
- Jul 10, 2026IPOApnimed Files for Nasdaq IPO on First Oral Sleep Apnea Pill→
All Coverage
IPO
Consumer IPOs Are Getting Crushed While Biotech Pops
Jersey Mike's opened 9% below its IPO price the same day Reformation traded flat, while Apnimed popped 37.5% days later -- public investors are rewarding unmet-need biotech and discounting mature consumer brands.
Apnimed Soars 37% in Nasdaq Debut for Sleep Apnea Pill
IPO$192M IPO
Apnimed Soars 37% in Nasdaq Debut for Sleep Apnea Pill
Apnimed shares jumped as much as 37.5% in their Nasdaq debut after the Phase 3 biotech priced its upsized IPO at $16 a share, raising $192 million to fund what could become the first FDA-approved pill for obstructive sleep apnea.
Apnimed Prices Upsized IPO at $16, Raises $192M
IPO$192M IPO
Apnimed Prices Upsized IPO at $16, Raises $192M
Apnimed priced an upsized IPO at $16 per share, raising $192 million ahead of its Nasdaq debut under ticker APMD, betting on the first potential FDA-approved pill for obstructive sleep apnea.
Apnimed Launches $150M IPO for Sleep Apnea Pill
IPO$150M-$160M IPO
Apnimed Launches $150M IPO for Sleep Apnea Pill
Apnimed launched a $150-160 million IPO for a pill that could become the first FDA-approved treatment for obstructive sleep apnea.
Apnimed Launches $150M IPO For First Sleep Apnea Pill
IPOup to $150M IPO
Apnimed Launches $150M IPO For First Sleep Apnea Pill
Shionogi-backed Apnimed launched a $150 million IPO for its once-daily obstructive sleep apnea pill AD109, targeting a Thursday pricing ahead of a Friday NASDAQ debut.
Apnimed Files for Nasdaq IPO on First Oral Sleep Apnea Pill
IPO
Apnimed Files for Nasdaq IPO on First Oral Sleep Apnea Pill
Apnimed, a Shionogi-backed clinical-stage biotech, filed for a Nasdaq IPO under ticker APMD as its lead drug candidate Oxnimbi -- the first investigational oral pill for obstructive sleep apnea -- awaits an FDA decision expected in Q1 2027.
Related Companies
Apnimed FAQ
Who is the CEO of Apnimed?
Kevin Lind is chief executive.[3]
Is Apnimed a public company?
Apnimed began trading on the Nasdaq Global Select Market under the ticker APMD on July 31, 2026.[1]
Where is Apnimed headquartered?
Apnimed is based in Cambridge, Massachusetts.[1]
What does Apnimed do?
Apnimed is a late-stage pharmaceutical company developing oral drugs for obstructive sleep apnea and related breathing disorders.[1]
What is Apnimed's market cap?
Apnimed's market capitalization was $1.52B as of September 4, 2026, according to stockanalysis.com.
When was Apnimed founded and where is it based?
Apnimed was founded in 2017 and is headquartered in Cambridge, Massachusetts, USA, according to Wikidata and Apnimed.
References
researched 2026-10-24Sources & methodologyshow
Where these figures come from
- stockanalysis.comresearch database1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.